Entering text into the input field will update the search result below

ALX Oncology gets dosing underway in Phase 1/2 evorpacept leukemia study

Skin cancer cells

Dr_Microbe/iStock via Getty Images

  • ALX Oncology Holdings (NASDAQ:ALXO) announces that the first patient has been dosed in the Phase 1/2 ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).

Recommended For You

More Trending News

About ALXO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALXO--
ALX Oncology Holdings Inc.